Implications of the RELEVANCE Study and Optimal Use of R² in Second-Line Follicular Lymphoma

EP: 1.Introduction and Exploring the Financial Burden of Follicular Lymphoma

EP: 2.Optimizing First- and Second-Line Treatment Strategies in Follicular Lymphoma

EP: 3.Advancing Care in Relapsed/Refractory Follicular Lymphoma Beyond Chemotherapy

EP: 4.Integrating Bispecific Antibodies and Evolving Strategies in Relapsed/Refractory Follicular Lymphoma

Now Viewing

EP: 5.Implications of the RELEVANCE Study and Optimal Use of R² in Second-Line Follicular Lymphoma

EP: 6.Targeted Therapies and Bispecific Antibodies in Second-Line Follicular Lymphoma

The RELEVANCE study was pivotal in demonstrating that a non-chemotherapy approach—rituximab combined with lenalidomide (R²)—could achieve outcomes comparable to traditional chemoimmunotherapy in follicular lymphoma. Its findings validated R² as a viable option in the second-line setting, particularly for patients seeking effective yet less cytotoxic regimens. The trial reinforced the role of immunomodulatory therapy in a disease marked by repeated relapses and the need for durable, well-tolerated strategies. Providers adopting R² must be attentive to characteristic adverse events such as cytopenias, rash, fatigue, and thromboembolic risk. These can be effectively managed through dose adjustments, supportive medications, and routine monitoring. By understanding both the efficacy and safety considerations, clinicians can integrate R² confidently into personalized treatment plans.